A cell-permeable, reversible, and potent antioxidant that has anti-mutagenic and anti-carcinogenic properties. Acts as a selective and ATP-competitive inhibitor of CK2 (IC₅₀ = 40 nM). Moderately inhibits DNA topoisomerases I and II, Lyn, PKA catalytic subunit, Lyk, GSK-3, PKC, and FGR (IC₅₀ = 1.8, 2.1, 2.9, 3.5, 4.3, 7.5, 8.0, and 9.4 µM, respectively). Only minimally inhibits DYRK1a, CSK, RET, Flt3, and NPM-ALK (IC₅₀ >40 µM). Shown to act as an uncompetitive inhibitor of arginine methyltransferase CARM1 and block histone H3R17 methylation.

A cell-permeable, reversible, potent antioxidant that has anti-mutagenic and anti-carcinogenic properties. Acts as a selective and ATP-competitive inhibitor of CK2 (IC₅₀ = 40 nM). Moderately inhibits DNA topoisomerases I and II, Lyn, PKA catalytic subunit, Lyk, GSK-3, PKC, and FGR (IC₅₀ = 1.8, 2.1, 2.9, 3.5, 4.3, 7.5, 8.0, and 9.4 µM, respectively). Only minimally inhibits DYRK1a, CSK, RET, Flt3, and NPM-ALK (IC₅₀ >40 µM). Shown to act as an uncompetitive inhibitor of arginine methyltransferase CARM1 and block histone H3R17 methylation.

Cell permeable: yes

Primary Target
CDK2

Product competes with ATP.

Reversible: yes

Target IC₅₀: 40 nM against CK2; 1.8, 2.1, 2.9, 3.5, 4.3, 7.5, 8.0, and 9.4 µM, against DNA topoisomerases I and II, Lyn, PKA catalytic subunit, Lyk, GSK-3, PKC, and FGR, respectively

Packaged under inert gas

Following reconstitution, aliquot and freeze (-20°C). Ethanol stock solutions are stable for up to 1 week at -20°C. Alkaline solutions are unstable and should be prepared just prior to use.

For complete solubilization in ethanol, slight heating may be required.

Selvi, B.R., et al. 2009, J. Biol. Chem. In press.
Cozza, G., et al. 2006. J. Med. Chem.49, 2363.
Wang, B.H., et al. 1998. Planta Med. 64, 195.
Constantinou, A., et al. 1995. Nutr. Cancer23, 121.
Hickey, M.J., et al. 1995. Biochem. Soc. Trans.23, 607s.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Irritant (B)